Note

再鼎医药(ZLAB.US)与Cullinan Pearl达成CLN-081的大中华区独家授权协议

· Views 117
再鼎医药(ZLAB.US)与Cullinan Pearl达成CLN-081的大中华区独家授权协议 © Reuters. 再鼎医药(ZLAB.US)与Cullinan Pearl达成CLN-081的大中华区独家授权协议

智通财经APP获悉,再鼎医药(ZLAB.US)宣布,公司已获得Cullinan Pearl的EGFR抑制剂CLN-081在大中华区的独家开发,制造和商业化的许可授权。

根据协议,Cullinan Pearl将获得一笔2000万美元的预付款,以及获得最高至2.11亿美元的开发、注册和基于销售的里程碑付款。此外,再鼎医药将根据CLN-081在大中华区的年度净销售额向Cullinan Pearl支付高单位数至低双位数的特许权使用费。

Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.

FOLLOWME Trading Community Website: https://www.followme.com

If you like, reward to support.
avatar

Hot

No comment on record. Start new comment.